title: Neutrophilic dermatosis complicating lenalidomide therapy.
abstract: Lenalidomide, a derivative of thalidomide, is an immunomodulatory agent introduced in 2004 for the treatment of multiple myeloma in combination with dexamethasone. It is also indicated for the treatment of myelodysplastic syndrome and is currently under investigative use for metastatic melanoma. We present a case of neutrophilic dermatosis involving predominantly the lower extremities in a patient receiving lenalidomide therapy for multiple myeloma.
authors: Harvard Medical School, Boston, Massachusetts, USA.
authors: Khanh P
authors: KP
authors: Thieu
authors: Misha
authors: M
authors: Rosenbach
authors: Xiaowei
authors: X
authors: Xu
authors: Joseph M
authors: JM
authors: Kist
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001706:Biopsy; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D012867:Skin / Q000473:pathology; D016463:Sweet Syndrome / Q000139:chemically induced* / Q000473:pathology; D013792:Thalidomide / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide